Cell & Gene Therapy Market by Product, Delivery Method, Application, End-User

List of Tables

The Cell & Gene Therapy Market was valued at USD 27.70 billion in 2023, expected to reach USD 34.63 billion in 2024, and is projected to grow at a CAGR of 25.39%, to USD 135.04 billion by 2030.

Cell and gene therapy (CGT) encompasses the use of biological treatments that modify or introduce genetic material into a patient's cells to treat or prevent disease. This evolving sector is notably vital for addressing unmet medical needs, especially for rare genetic disorders, cancers, and certain chronic conditions. Increasing investments in genomic research, advanced clinical trials, and the acceleration through expedited regulatory pathways like the FDA's regenerative medicine advanced therapy designation have catalyzed growth. Applications span from oncology, where therapies like CAR-T have shown remarkable remission rates, to regenerative medicine treating neurological disorders and cardiovascular diseases. The end-use potential extends to hospitals, cancer treatment centers, and specialized clinics. The market is experiencing significant growth driven by advances in CRISPR technology, personalized medicine approaches, and an increasing prevalence of chronic diseases. Opportunities lie in expanding the indications covered by CGT, establishing robust manufacturing capabilities, and biopharma collaborations to enhance therapy specificity and delivery mechanisms. However, challenges remain, including high development and therapy costs, complex manufacturing processes, and strict regulatory requirements. Additionally, ethical concerns over genetic modifications and potential long-term impacts pose hurdles. To foster innovation, research into off-the-shelf allogeneic therapies, enhanced vector designs for efficient gene delivery, and AI-driven drug discovery for targeted therapies can provide significant advancements. Furthermore, enhancing patient access through strategic pricing models and in-depth public-private partnerships can address market barriers. Market growth is currently dynamic, spurred by rapid technological advancements and growing approval rates, yet tempered by production scalability issues and variable reimbursement landscapes. Moving forward, a focus on overcoming delivery challenges, optimizing manufacturing processes, and prioritizing patient-centric models will be pivotal in capitalizing on the burgeoning opportunities of the cell and gene therapy sector.

KEY MARKET STATISTICS
Base Year [2023]	USD 27.70 billion
Estimated Year [2024]	USD 34.63 billion
Forecast Year [2030]	USD 135.04 billion
CAGR (%)	25.39%

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Cell & Gene Therapy Market

The Cell & Gene Therapy Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

Market Drivers
- Rising prevalence of chronic diseases and significance for gene therapy treatment
- Growing awareness of gene & cell therapies coupled with increase in healthcare expenditure
- Significant growth in numbers of clinical trials and increasing governmental approvals
Market Restraints
- High costs asscoiated with the gene and cell therapy treatment
Market Opportunities
- Emergence of advanced analytical technologies in development of cell & gene
- Rising investments in pharmaceutical and biopharmaceutical research
Market Challenges
- Unavailability of reimbursement policies for cell & gene therapies

Porter's Five Forces: A Strategic Tool for Navigating the Cell & Gene Therapy Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Cell & Gene Therapy Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Cell & Gene Therapy Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Cell & Gene Therapy Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Cell & Gene Therapy Market

A detailed market share analysis in the Cell & Gene Therapy Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Cell & Gene Therapy Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Cell & Gene Therapy Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Cell & Gene Therapy Market

A strategic analysis of the Cell & Gene Therapy Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Cell & Gene Therapy Market, highlighting leading vendors and their innovative profiles. These include Abeona Therapeutics Inc., Adaptimmune Limited, AGC Biologics, Alnylam Pharmaceuticals, Inc., American Gene Technologies Inc., Amgen Inc., AnGes, Inc., Astellas Gene Therapies, Beacon Therapeutics Limited, Biogen Inc., bluebird bio, Inc., Cellectis SA, Editas Medicine, Inc., F. Hoffmann-La Roche Ltd, Immuneel Therapeutics Private Limited, Ionis Pharmaceuticals, Inc., Merck KGaA, Mustang Bio, Inc., Novartis AG, Orchard Therapeutics PLC, Poseida Therapeutics, Inc., Sangamo Therapeutics, Inc., Sarepta Therapeutics, Inc., Sibiono GeneTech Co. Ltd., and Uniqure N.V..

Market Segmentation & Coverage

This research report categorizes the Cell & Gene Therapy Market to forecast the revenues and analyze trends in each of the following sub-markets:

Based on Product, market is studied across Cell Therapy and Gene Therapy.
Based on Delivery Method, market is studied across Ex Vivo and In Vivo.
Based on Application, market is studied across Dermatology, Musculoskeletal, and Oncology.
Based on End-User, market is studied across Ambulatory Surgical Centers, Cancer Care Centers, Hospitals, and Wound Care Centers.
Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Product Code: MRR-450A0628CE5A

1. Preface

1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Stakeholders

2. Research Methodology

2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

5.1. Market Dynamics
- 5.1.1. Drivers
  - 5.1.1.1. Rising prevalence of chronic diseases and significance for gene therapy treatment
  - 5.1.1.2. Growing awareness of gene & cell therapies coupled with increase in healthcare expenditure
  - 5.1.1.3. Significant growth in numbers of clinical trials and increasing governmental approvals
- 5.1.2. Restraints
  - 5.1.2.1. High costs asscoiated with the gene and cell therapy treatment
- 5.1.3. Opportunities
  - 5.1.3.1. Emergence of advanced analytical technologies in development of cell & gene
  - 5.1.3.2. Rising investments in pharmaceutical and biopharmaceutical research
- 5.1.4. Challenges
  - 5.1.4.1. Unavailability of reimbursement policies for cell & gene therapies
5.2. Market Segmentation Analysis
5.3. Porter's Five Forces Analysis
- 5.3.1. Threat of New Entrants
- 5.3.2. Threat of Substitutes
- 5.3.3. Bargaining Power of Customers
- 5.3.4. Bargaining Power of Suppliers
- 5.3.5. Industry Rivalry
5.4. PESTLE Analysis
- 5.4.1. Political
- 5.4.2. Economic
- 5.4.3. Social
- 5.4.4. Technological
- 5.4.5. Legal
- 5.4.6. Environmental

6. Cell & Gene Therapy Market, by Product

6.1. Introduction
6.2. Cell Therapy
6.3. Gene Therapy

7. Cell & Gene Therapy Market, by Delivery Method

7.1. Introduction
7.2. Ex Vivo
7.3. In Vivo

8. Cell & Gene Therapy Market, by Application

8.1. Introduction
8.2. Dermatology
8.3. Musculoskeletal
8.4. Oncology

9. Cell & Gene Therapy Market, by End-User

9.1. Introduction
9.2. Ambulatory Surgical Centers
9.3. Cancer Care Centers
9.4. Hospitals
9.5. Wound Care Centers

10. Americas Cell & Gene Therapy Market

10.1. Introduction
10.2. Argentina
10.3. Brazil
10.4. Canada
10.5. Mexico
10.6. United States

11. Asia-Pacific Cell & Gene Therapy Market

11.1. Introduction
11.2. Australia
11.3. China
11.4. India
11.5. Indonesia
11.6. Japan
11.7. Malaysia
11.8. Philippines
11.9. Singapore
11.10. South Korea
11.11. Taiwan
11.12. Thailand
11.13. Vietnam

12. Europe, Middle East & Africa Cell & Gene Therapy Market

12.1. Introduction
12.2. Denmark
12.3. Egypt
12.4. Finland
12.5. France
12.6. Germany
12.7. Israel
12.8. Italy
12.9. Netherlands
12.10. Nigeria
12.11. Norway
12.12. Poland
12.13. Qatar
12.14. Russia
12.15. Saudi Arabia
12.16. South Africa
12.17. Spain
12.18. Sweden
12.19. Switzerland
12.20. Turkey
12.21. United Arab Emirates
12.22. United Kingdom

13. Competitive Landscape

13.1. Market Share Analysis, 2023
13.2. FPNV Positioning Matrix, 2023
13.3. Competitive Scenario Analysis
13.4. Strategy Analysis & Recommendation

Companies Mentioned

1. Abeona Therapeutics Inc.
2. Adaptimmune Limited
3. AGC Biologics
4. Alnylam Pharmaceuticals, Inc.
5. American Gene Technologies Inc.
6. Amgen Inc.
7. AnGes, Inc.
8. Astellas Gene Therapies
9. Beacon Therapeutics Limited
10. Biogen Inc.
11. bluebird bio, Inc.
12. Cellectis SA
13. Editas Medicine, Inc.
14. F. Hoffmann-La Roche Ltd
15. Immuneel Therapeutics Private Limited
16. Ionis Pharmaceuticals, Inc.
17. Merck KGaA
18. Mustang Bio, Inc.
19. Novartis AG
20. Orchard Therapeutics PLC
21. Poseida Therapeutics, Inc.
22. Sangamo Therapeutics, Inc.
23. Sarepta Therapeutics, Inc.
24. Sibiono GeneTech Co. Ltd.
25. Uniqure N.V.